Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruconest for acute attacks of hereditary angioedema
NCT00262288Phase 3Completed
- Sponsor
- Pharming Group
- Start
- Apr 2004
- Primary completion
- Jan 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of c1-esterase inhibitor in hereditary angioedema (HAE), sponsored by Pharming Group. Primary endpoint: Time to beginning of relief of angioedema symptoms at 24 hours. Started Apr 2004; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT00262288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262288.